Medicare to Offer Discounted Weight-Loss GLP-1 Drugs in New Pilot

Millions of Medicare beneficiaries may soon get a cheaper path to some weight-loss GLP-1 drugs, but the federal opening is narrow and temporary. The Centers for Medicare & Medicaid Services set up a Medicare GLP-1 Bridge that will run from July 1, 2026, through December 31, 2027, and said it will operate outside the normal Medicare Part D coverage and payment flow.

That structure matters. Part D sponsors will not carry the financial risk for the eligible drugs, and they do not have to opt in for beneficiaries to access them. CMS also said it will use a single central processor in 2026 to handle prior authorization, claims adjudication and pharmacy payment, a sign that the agency expects administrative complexity even before the first prescriptions are filled.

The bridge will cover certain GLP-1 drugs approved for weight loss, including Wegovy and Zepbound. CMS guidance also includes Foundayo. The expected copay is $50, which is far below the list and cash prices many older adults face now, but it is not free coverage. Eligibility is limited to people already enrolled in Medicare Part D, and the clinical screens are strict: people with a body mass index of 35 or higher automatically qualify, while those with a BMI of 27 or higher must also have a related condition such as heart disease or prediabetes.

The policy reflects a long fight over whether Medicare can pay for obesity treatment at all. The Medicare Prescription Drug, Improvement, and Modernization Act of 2003 barred coverage for drugs used for anorexia, weight loss or weight gain. KFF says Medicare still covers GLP-1s when they are used for type 2 diabetes, cardiovascular disease and sleep apnea, but not for weight loss because of that statutory limit. In 2024, the Administration for Strategic Preparedness and Response said a proposed reinterpretation would not apply when the drugs are used to treat beneficiaries with obesity, and the final 2026 rule did not include the broader anti-obesity coverage idea.

The political pressure is obvious. Obesity remains common among older Americans, the drugs are expensive, and affordability remains a major barrier. KFF has estimated Wegovy’s annual net price at about $13,600, while current cash prices for GLP-1 weight-loss drugs typically run from $149 to $699 a month. A WKNO/NPR report said about half of GLP-1 users find the drugs difficult to afford, and about a quarter say they are very difficult to afford.

CMS Administrator Dr. Mehmet Oz said the BALANCE Model builds on the administration’s Most Favored Nation drug pricing deals and is meant to expand access. CMS Innovation Center Director Abe Sutton said it pairs drug access with evidence-based lifestyle support and will be judged on costs, adherence, outcomes and beneficiary experience. Eli Lilly has said Medicare beneficiaries with obesity or overweight would have access to Zepbound and, if approved, orforglipron at $50 a month starting as early as April 1, 2026. Even so, the bridge looks less like a universal benefit than a tightly managed test, one that could help some seniors but is unlikely to open the door for all who want these drugs.